Age-related macular degeneration

The Lancet

Volumn 372, Issue 9652, 2008, Pages 1835-1845

  Coleman, Hanna R ^a   Chan, Chi Chao ^a   Ferris III, Frederick L ^a   Chew, Emily Y ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ANTIOXIDANT; ASCORBIC ACID; BETA CAROTENE; BEVACIZUMAB; COMPLEMENT FACTOR H; COPPER; OMEGA 3 FATTY ACID; PEGAPTANIB; RANIBIZUMAB; VASCULOTROPIN; VASCULOTROPIN INHIBITOR; VITAMIN; XANTHOPHYLL; ZEAXANTHIN; ZINC; ZINC OXIDE;

AGING; BLINDNESS; CIGARETTE SMOKING; CLINICAL TRIAL; DRUG INHIBITION; ENDOPHTHALMITIS; ENVIRONMENTAL FACTOR; EUROPE; GENETIC RISK; HEREDITY; HUMAN; LASER COAGULATION; LASER SURGERY; LENS DISEASE; LENS INJURY; MORBIDITY; MULTIPLE CYCLE TREATMENT; OXIDATIVE STRESS; PATHOGENESIS; PATHOPHYSIOLOGY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROPHYLAXIS; RETINA DETACHMENT; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RISK REDUCTION; UVEITIS; VISION; VISUAL IMPAIRMENT;

EID: 56249140828     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61759-6     Document Type: Review

References (166)

1. The Eye Diseases Prevalence Research Group. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 122 (2004) 477-485
2. The Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss. Arch Ophthalmol 119 (2001) 1417-1436
3. Bird A.C., Bressler N.M., Bressler S.B., et al., The International ARM Epidemiological Study Group. An international classification and grading system for age-related maculopathy and age-related macular degeneration. Surv Ophthalmol 39 (1995) 367-374
4. Vingerling J.R., Dielemans I., Hofman A., et al. The prevalence of age-related maculopathy in the Rotterdam Study. Ophthalmology 102 (1995) 205-210
5. Munoz B., West S.K., Rubin G.S., et al. Causes of blindness and visual impairment in a population of older Americans: the Salisbury Eye Evaluation Study. Arch Ophthalmol 118 (2000) 819-825
6. Weih L.M., VanNewkirk M.R., McCarty C.A., and Taylor H.R. Age-specific causes of bilateral visual impairment. Arch Ophthalmol 118 (2000) 264-269
7. Age-Related Eye Disease Study Research Group. The Age-Related Eye Disease Study severity scale for age-related macular degeneration. Arch Ophthalmol 123 (2005) 1484-1498
8. Age-Related Eye Disease Study Research Group. A simplified severity scale for age-related macular degeneration. Arch Ophthalmol 123 (2005) 1570-1574
9. de Jong P.T. Age-related macular degeneration. N Engl J Med 355 (2006) 1474-1485
10. Ambati J., Ambati B.K., Yoo S.H., Ianchulev S., and Adamis A.P. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 48 (2003) 257-293
11. Zarbin M.A. Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 122 (2004) 598-614
12. Holz F.G., Pauleikhoff D., Klein R., and Bird A.C. Pathogenesis of lesions in late age-related macular disease. Am J Ophthalmol 137 (2004) 504-510
13. Nussenblatt R.B., and Ferris F.L. Age-related macular degeneration and the immune response: implications for therapy. Am J Ophthalmol 144 (2007) 618-626
14. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results. Arch Ophthalmol 121 (2003) 1621-1624
15. Bunce C., and Wormald R. Causes of blind certifications in England and Wales: April 1999-March 2000. Eye 22 (2008) 905-911
16. Smith W., Assink J., Klein R., et al. Risk factors for age-related macular degeneration: pooled findings from three continents. Ophthalmology 108 (2001) 697-704
17. Mitchell P., Wang J.J., Foran S., and Smith W. Five-year incidence of age-related maculopathy lesions: the Blue Mountains Eye Study. Ophthalmology 109 (2002) 1092-1097
18. Wang J.J., Foran S., and Mitchell P. Age-specific prevalence and causes of bilateral and unilateral visual impairment in older Australians: the Blue Mountains Eye Study. Clin Experiment Ophthalmol 28 (2000) 268-273
19. Klein R., Klein B.E., Knudtson M.D., Meuer S.M., Swift M., and Gangnon R.E. Fifteen-year cumulative indicence of age-related macular degeneration. Ophthalmology 114 (2007) 253-262
20. van Leeuwen R., Klaver C.C., Vingerling J.R., Hofman A., and de Jong P.T. The risk and natural course of age-related maculopathy: follow-up at 61/2 years in the Rotterdam Study. Arch Ophthalmol 121 (2003) 519-526
21. Mukesh B.N., Dimitrov P.N., Leikin S., et al. Five year incidence of age-related maculopathy: Visual Impairment Project. Ophthalmology 111 (2004) 1176-1182
22. Mitchell P., Smith W., Attebo K., et al. Prevalence of age-related maculopathy in Australia. Ophthalmology 102 (1995) 1450-1460
23. Klein R., Klein B.E., and Linton K.L. Prevalence of age-related maculopathy. Ophthalmology 99 (1992) 933-943
24. Cruickshanks K.J., Hamman R.F., Klein R., et al. The prevalence of age-related maculopathy by geographic region and ethnicity. Arch Ophthalmol 115 (1997) 242-250
25. Friedman D.S., Katz J., Bressler N.M., et al. Racial differences in the prevalence of age-related macular degeneration: the Baltimore Eye Survey. Ophthalmology 106 (1999) 1049-1055
26. Bressler N.M., Bressler S.B., West S.K., et al. The grading and prevalence of macular degeneration in Chesapeake Bay waterman. Arch Ophthalmol 107 (1989) 847-852
27. VanNewkirk M.R., Nanjan M.B., Wanh J.J., et al. The prevalence of age-related maculopathy: the visual impairment project. Ophthalmology 107 (2000) 1593-1600
28. The Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration: a case-control study in the Age-Related Eye Disease Study. Ophthalmology 107 (2000) 2224-2232
29. Delcourt C., Diaz J.L., Ponton-Sanchez A., and Papoz L. Smoking and age-related macular degeneration. Arch Ophthalmol 116 (1998) 1031-1035
30. Hyman L.G., Lilienfeld A.M., Ferris III F.L., et al. Senile macular degeneration: a case-control study. Am J Epidemiol 118 (1983) 213-227
31. Vinding T., Appleyard M., Nyboe J., et al. Risk factor analysis for atrophic and exudative age-related macular degeneration. An epidemiologic study of 1000 aged individuals. Acta Ophthalmol 70 (1992) 215-222
32. McCarty C.A., Mukesh B.N., Fu C.L., et al. Risk factors for age-related maculopathy: the Visual Impairment Project. Arch Ophthalmol 119 (2001) 1455-1462
33. The Eye Disease Case-Control Study Group. Risk factors for neovascular age-related macular degeneration. Arch Ophthalmol 110 (1992) 1701-1708
34. Vingerling J.R., Hofman A., Grobbee D.E., et al. Age-related macular degeneration and smoking. Arch Ophthalmol 114 (1996) 1193-1196
35. Klein R., Klein B., Linton K.L., et al. The Beaver Dam Eye Study: the relation of age-related maculopathy to smoking. Am J Epidemiol 137 (1993) 190-200
36. Smith W., Mitchell P., and Leeder S.R. Smoking and age-related maculopathy. Arch Ophthalmol 114 (1996) 1518-1523
37. Seddon J.M., Willett W.C., Speizer F.E., et al. A prospective study of cigarette smoking and age-related macular degeneration in women. JAMA 276 (1996) 1141-1146
38. Christen W.G., Glynn R.J., Manson F.E., et al. A prospective study of cigarette smoking and risk of age-related macular degeneration in men. JAMA 276 (1996) 1147-1151
39. Khan J.C., Thurlby D.A., Shahid H., et al. Smoking and age-related macular degeneration: the number of pack years of cigarette smoking is a major determinant of risk for both geographic atrophy and choroidal neovascularization. Br J Ophthalmol 90 (2006) 75-80
40. Chaine G., Hullo A., Sahel J., et al. Case-control study of the risk factors for age related macular degeneration. Br J Ophthalmol 276 (1998) 996-1002
41. Klein R., Klein B.E., Jenson S.C., et al. Age-related maculopathy in a multiracial United States population: the National Health and Nutrition Examination Survey III. Ophthalmology 106 (1999) 1056-1065
42. Schachat A.P., Hyman L., Leske M.C., et al. Features of age-related macular degeneration in a black population. Arch Ophthalmol 113 (1995) 728-735
43. Klein R., Klein B.E., Knudtson M.D., et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis. Ophthalmology 113 (2006) 373-380
44. Haddad S., Chen C.A., Santangelo S.L., and Seddon J.M. The genetics of age-related macular degeneration: a review of progress to date. Surv Ophthalmol 51 (2006) 316-363
45. Scholl H.P.N., Fleckenstein M., Issa P.C., Keilhauer C., Holz F.G., and Weber B.H. An update on the genetics of age-related macular degeneration. Mol Vis 13 (2007) 196-205
46. Heiba I.M., Elston R.C., Klein B.E., and Klein R. Sibling correlations and segregation analysis of age-related maculopathy: the Beaver Dam Eye Study. Genet Epidemiol 11 (1994) 51-67
47. Klaver C.C., Wolfs R.C., Assink J.J., et al. Genetic risk of age-related maculopathy. Population-based familial aggregation study. Arch Ophthalmol 116 (1998) 1646-1651
48. Seddon J.M., Ajani U.A., and Mitchell B.D. Familial aggregation of age-related maculopathy. Am J Ophthalmol 123 (1997) 199-206
49. Smith W., and Mitchell P. Family history and age-related maculopathy: the Blue Mountains Eye Study. Aust N Z J Ophthalmol 26 (1998) 203-206
50. Gottfredsdottir M.S., Sverrisson T., Musch D.C., et al. Age related macular degeneration in monozygotic twins and their spouses in Iceland. Acta Ophthalmol Scand 77 (1999) 422-425
51. Klein M.L., Maudlin W.M., and Stoumbos V.D. Heredity and age-related macular degeneration. Observations in monozygotic twins. Arch Ophthalmol 112 (1994) 932-937
52. Meyers S.M., Greene T., and Gutman F.A. A twin study of age-related macular degeneration. Am J Ophthalmol 120 (1995) 757-766
53. Seddon J.M., Cote J., Page W.F., Aggen S.H., and Neale M.C. The US twin study of age-related macular degeneration: relative roles of genetic and environmental influences. Arch Ophthalmol 123 (2005) 321-327
54. Klein R.J., Zeiss C., Chew E.Y., et al. Complement factor H polymorphism in age-related macular degeneration. Science 308 (2005) 385-389
55. Edwards A.O., Ritter III R., Abel K.J., Manning A., Panhuysen C., and Farrer L.A. Complement factor H polymorphism and age-related macular degeneration. Science 308 (2005) 421-424
56. Haines J.L., Hauser M.A., Schmidt S., et al. Complement factor H variant increases the risk of age-related macular degeneration. Science 308 (2005) 419-421
57. Hageman G.S., Anderson D.H., Johnson L.V., et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 102 (2005) 7227-7232
58. Conley Y.P., Thalamuthu A., Jakobsdottir J., et al. Candidate gene analysis suggests a role for fatty acid biosynthesis and regulation of the complement system in the etiology of age-related maculopathy. Hum Mol Genet 14 (2005) 1991-2002
59. Zareparsi S., Branham K.E., Li M., et al. Strong association of the Y402H variant in complement factor H at 1q32 with susceptibility to age-related macular degeneration. Am J Hum Genet 77 (2005) 149-153
60. Rivera A., Fisher S.A., Fritsche L.G., et al. Hypothetical LOC387715 is a second major susceptibility gene for age-related macular degeneration contributing independently of complement factor H to disease risk. Hum Mol Genet 14 (2005) 3227-3236
61. Souied E.H., Leveziel N., Richard F., et al. Y402H complement factor H polymorphism associated with exudative age-related macular degeneration in the French population. Mol Vis 11 (2005) 1135-1140
62. Sepp T., Khan J.C., Thurlby D.A., et al. Complement factor H variant Y402H is a major risk determinant for geographic atrophy and choroidal neovascularization in smokers and nonsmokers. Invest Ophthalmol Vis Sci 47 (2006) 536-540
63. Magnusson K.P., Duan S., Sigurdsson H., et al. CFH Y402H confers similar risk of soft drusen and both forms of advanced AMD. PLoS Med 3 (2005) e5
64. Lau L.I., Chen S.J., Cheng C.Y., et al. Association of the Y402H polymorphism in complement factor H gene and neovascular age-related macular degeneration in Chinese patients. Invest Ophthalmol Vis Sci 47 (2006) 3242-3246
65. Okamoto H., Umeda S., Obazawa M., et al. Complement factor H polymorphisms in Japanese population with age-related macular degeneration. Mol Vis 12 (2006) 156-158
66. Gold B., Merriam J.E., Zernant J., et al. Variation in factor B (BF) and complement component 2 (C2) genes is associated with age-related macular degeneration. Nat Genet 38 (2006) 458-462
67. Yates Y.R., Sepp T., Matharu B.K., et al. Complement C3 variant and the risk of age-related macular degeneration. N Engl J Med 357 (2007) 19-27
68. Jakobsdottir J., Conley Y.P., Weeks D.E., Mah T.S., Ferrell R.E., and Gorin M.B. Susceptibility genes for age-related maculopathy on chromosome 10q26. Am J Hum Genet 77 (2005) 389-407
69. Dewan A., Liu M., Hartman S., et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science 314 (2006) 989-992
70. Seddon J.M., Francis P.J., George S., Schultz D.W., Rosner B., and Klein M.I. Association of CFH Y402H and LOC387715 A69S with progression of age-related macular degeneration. JAMA 297 (2007) 1793-1800
71. Ross R.J., Bojanowski C.M., Wang J.J., et al. The LOC387715 polymorphism and age-related macular degeneration replication in 3 case-control samples. Invest Ophthalmol Vis Sci 48 (2007) 1128-1132
72. Yang Z., Camp N.J., Sun H., et al. A variant of the HTRA1 gene increases susceptibility to age-related macular degeneration. Science 314 (2006) 992-993
73. Francis P.J., George S., Schultz D.W., et al. The LOC387715 gene, smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum Hered 63 (2007) 212-218
74. Schmidt S., Hauser M.A., Scott W.K., et al. Cigarette smoking strongly modifies the association of LOC387715 and age-related macular degeneration. Am J Hum Genet 78 (2006) 852-864
75. Seddon J.M., George S., Rosner B., and Klein M.L. CFH gene variant, Y402H, and smoking, body mass index, environmental associations with advanced age-related macular degeneration. Hum Hered 61 (2006) 157-165
76. Duan Y., Mo J., Klein R., et al. Age-related macular degeneration is associated with incident myocardial infarction among elderly Americans. Ophthalmology 114 (2007) 732-737
77. Wong T.Y., Tikellis, Sun C., Klein R., Douper D.J., and Sharrett A.R. Age-related macular degeneration and risk of coronary heart disease: the Atherosclerosis Risk in Communities Study. Ophthalmology 114 (2007) 86-91
78. Tan J.S., Mitchell P., Smith W., and Wang J.J. Cardiovascular risk factors and the long-term incidence of age-related macular degeneration. Ophthalmology 125 (2007) 1089-1095
79. Klein R., Deng Y., Klein B.E., et al. Cardiovascular disease, its risk factors and treatment and age-related macular degeneration: Women's Health Initiative Sight Exam ancillary Study. Am J Ophthalmol 143 (2007) 473-483
80. Hyman L., Schachat A.P., He Q., and Leske M.C. Hypertension, cardiovascular disease, and age-related macular degeneration. Arch Ophthalmol 118 (2000) 351-358
81. Tomany S.C., Wang J.J., van Leeuwen R., et al. Risk factors for incident age-related macular degeneration. Pooled findings from 3 continents. Ophthalmology 111 (2004) 1280-1287
82. Delcourt C., Michel F., Colvez A., et al. Associations of cardiovascular disease and its risk factors with age-related macular degeneration: the POLA study. Ophthalmic Epidemiol 8 (2001) 237-249
83. Mares-Perlman J.A., Brady W.E., Klein R., et al. Dietary fat and age-related maculopathy. Arch Ophthalmol 113 (1995) 743-748
84. Cho E., Hung S., Willett C., et al. Prospective study of dietary fat and the risk of age-related macular degeneration. Am J Clin Nutr 73 (2001) 209-218
85. Heuberger R.A., Mares-Perlman J.A., Klein R., et al. Relationship of dietary fat to age-related maculopathy in the Third National Health and Nutrition Examination Survey. Arch Ophthalmol 119 (2001) 1833-1838
86. Seddon J.M., Rosner B., Sperduto R.D., et al. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol 119 (2001) 1191-1199
87. Klein R., Klein B.E., Tomany S.C., and Cruickshanks K.J. The association of cardiovascular disease with the long-term incidence of age-related maculopathy. Ophthalmology 110 (2003) 1273-1280
88. Fraser-Bell S., Wu J., Klein R., et al. Cardiovascular risk factors and age-related macular degeneration: the Los Angeles Latino Eye Study. Am J Ophthalmol 145 (2008) 308-316
89. Hogg R.E., Woodside J.V., Gilchrist S.E., et al. Cardiovascular disease and hypertension are strong risk factors for choroidal neovascularization. Ophthalmology 115 (2008) 1046-1052
90. Seddon J.M., Ajani U.A., Sperduto R.D., et al. Dietary carotenoids, vitamins A, C, and E, and advanced age-related macular degeneration. JAMA 272 (1994) 1413-1420
91. Snellen E.L., Verbeek A.L., Van Den Hoogen G.W., Cruysberg J.R., and Hoyng C.B. Neovascular age-related macular degeneration and its relationship to antioxidant intake. Acta Ophthalmol Scand 80 (2002) 368-371
92. Goldberg J., Flowerdew G., Smith E., Brody J.A., and Tso M.O. Factors associated with age-related macular degeneration: an analysis of data from the first National Health and Nutrition Examination Survey. Am J Epidemiol 128 (1988) 700-710
93. Van den Langenberg G.M., Mares-Perlman J.A., Klein R., Klein B.E., Brady W.E., and Palta M. Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study. Am J Epidemiol 148 (1998) 204-214
94. Flood V., Smith W., Wang J.J., Manzi F., Webb K., and Mitchell P. Dietary antioxidant intake and incidence of early age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 109 (2002) 2272-2278
95. Vu H.T.V., Robman L., McCarty C.A., Taylor H.R., and Hodge A. Does dietary lutein and zeaxanthin increase the risk of age-related macular degeneration?. Br Jr Ophthalmol 90 (2006) 389-390
96. Van Leeuwen R., Boekhoom S., Vingerling J.R., et al. Dietary intake of antioxidants and risk of age-related macular degeneration. JAMA 294 (2005) 3101-3107
97. Taylor H.R., Tikellis G., Robman L.D., McCarty C.A., and McNeil J.J. Vitamin E supplementation and macular degeneration: randomized controlled trial. BMJ 325 (2002) 11
98. Landrum J.T., and Bone R.A. Lutein, zeaxanthin, and the macular pigment. Arch Biochem Biophys 385 (2001) 28-40
99. Eye Disease Case-Control Study Group. Antioxidant status and neovascular age-related macular degeneration. Arch Ophthalmol 111 (1993) 104-109
100. SanGiovanni J.P., Chew E.Y., Clemons T.E., et al. The relationship of dietary carotenoid and vitamin A, E, and C intake with age-related macular degeneration in a case-control study. AREDS Report No. 22. Arch Ophthalmol 125 (2007) 1225-1232
101. Cho E., Seddon J.M., Rosner B., Willett W.C., and Hankinson S.E. Prospective study of intake of fruits, vegetables, vitamins, and carotenoids and risk of age-related maculopathy. Arch Ophthalmol 122 (2004) 883-892
102. Mares-Perlman J.A., Fisher A.I., Klein R., et al. Lutein and zeaxanthin in the diet and serum and their relation to age-related maculopathy in the third national health and nutrition examination survey. Am J Epidemiol 153 (2001) 424-432
103. Mares-Perlman J.A., Klein R., Klein B.E., et al. Association of zinc and antioxidant nutrients with age-related maculopathy. Arch Ophthalmol 114 (1996) 991-997
104. Krinsky N.I., Landrum J.T., and Bone R.A. Biologic mechanisms of the protective role of lutein and zeaxanthin in the eye. Annu Rev Nutr 23 (2003) 171-201
105. SanGiovanni J.P., Chew E.Y., Clemons T.E., et al. The relationship of dietary lipid intake and age-related macular degeneration in a case-control study. Arch Ophthalmol 125 (2007) 671-679
106. Seddon J.M., Rosner B., Sperduto R.D., et al. Dietary fat and risk for advanced age-related macular degeneration. Arch Ophthalmol 119 (2001) 1191-1199
107. Seddon J.M., Cote J., and Rosner B. Progression of age-related macular degeneration: association with dietary fat, transunsaturated fat, nuts, and fish intake. Arch Ophthalmol 121 (2003) 1728-1737
108. Chua B., Flood V., Rochtchina E., Wang J.J., Smith W., and Mitchell P. Dietary fatty acids and the 5-year incidence of age-related maculopathy. Arch Ophthalmol 124 (2006) 981-986
109. Hyman L.G., Lilienfeld A.M., Ferris III F.L., et al. Senile macular degeneration: a case-control study. Am J Epidemiol 118 (1983) 213-227
110. Klein R., Klein B.E., Jensen S.C., and Cruickshanks K.J. The relationship of ocular factors to the incidence and progression of age-related maculopathy. Arch Ophthalmol 116 (1998) 506-513
111. Taylor H.R., West S., Munoz B., Rosenthal F.S., Bressler S.B., and Bressler N.M. The long-term effects of visible light on the eye. Arch Ophtahlmol 110 (1992) 99-104
112. Delcourt C., Carriere I., Ponton-Sanchez A., et al. Light exposure and the risk of age-related macular degeneration: the POLA Study. Arch Ophthalmol 119 (2001) 1463-1468
113. Klein R., Klein B.E., Jensen S.C., and Cruickshanks K.J. Sunlight and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch Ophthalmol 119 (2001) 246-250
114. Klein R. Epidemiology. In: Berger J.W., Fine S.L., and Maguire M.G. (Eds). Age-related macular degeneration (1999), Mosby, Inc, St Louis 31-55
115. Green W.R., and Enger C. Age-related macular degeneration histopathologic studies. The 1992 Lorenz E Zimmerman Lecture. Ophthalmology 100 (1993) 1519-1535
116. Green W.R. Histopathology of age-related macular degeneration. Mol Vis 5 (1999) 27
117. Sarks S., Cherepanoff S., Killingsworth M., and Sarks J. Relationship of basal laminar deposit and membranous debris to the clinical presentation of early age-related macular degeneration. Invest Ophthalmol Vis Sci 48 (2007) 968-977
118. Mullins R.F., Russell S.R., Anderson D.H., and Hageman G.S. Drusen associated with aging and age-related macular degeneration contain proteins common to extracellular deposits associated with atherosclerosis, elastosis, amyloidosis, and dense deposit disease. Faseb J 14 (2000) 835-846
119. Mullins R.F., Johnson L.V., Anderson D.H., and Hageman G.S. Characterization of drusen-associated glycoconjugates. Ophthalmology 104 (1997) 288-294
120. Hageman G.S., Mullins R.F., Russell S.R., Johnson L.V., and Anderson D.H. Vitronectin is a constituent of ocular drusen and the vitronectin gene is expressed in human retinal pigmented epithelial cells. Faseb J 13 (1999) 477-484
121. Anderson D.H., Ozaki S., Nealon M., et al. Local cellular sources of apolipoprotein E in the human retina and retinal pigmented epithelium: implications for the process of drusen formation. Am J Ophthalmol 131 (2001) 767-781
122. Sarks S.H., Arnold J.J., Killingsworth M.C., and Sarks J.P. Early drusen formation in the normal and aging eye and their relation to age related maculopathy: a clinicopathological study. Br J Ophthalmol 83 (1999) 358-368
123. Gupta N., Brown K.E., and Milam A.H. Activated microglia in human retinitis pigmentosa, late-onset retinal degeneration, and age-related macular degeneration. Exp Eye Res 76 (2003) 463-467
124. Bressler N.M., Silva J.C., Bressler S.B., Fine S.L., and Green W.R. Clinicopathologic correlation of drusen and retinal pigment epithelial abnormalities in age-related macular degeneration. Retina 14 (1994) 130-142
125. Lutty G., Grunwald J., Majji A.B., Uyama M., and Yoneya S. Changes in choriocapillaris and retinal pigment epithelium in age-related macular degeneration. Mol Vis 5 (1999) 35
126. McLeod D.S., Taomoto M., Otsuji T., Green W.R., Sunness J.S., and Lutty G.A. Quantifying changes in RPE and choroidal vasculature in eyes with age-related macular degeneration. Invest Ophthalmol Vis Sci 43 (2002) 1986-1993
127. Kim S.Y., Sadda S., Humayun M.S., de Juan Jr. E., Melia B.M., and Green W.R. Morphometric analysis of the macula in eyes with geographic atrophy due to age-related macular degeneration. Retina 22 (2002) 464-470
128. Sparrow J.R., and Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 80 (2005) 595-606
129. Lamb L.E., and Simon J.D. A2E: a component of ocular lipofuscin. Photochem Photobiol 79 (2004) 127-136
130. Sparrow J.R., Fishkin N., Zhou J., et al. A2E, a byproduct of the visual cycle. Vision Res 43 (2003) 2983-2990
131. Schmitz-Valckenberg S., Bindewald-Wittich A., Dolar-Szczasny J., et al. Fundus autofluorescence in age-related macular degermation study group. Invest Ophthalmol Vis Sci 47 (2006) 2648-2654
132. Holz F.G., Bindewald-Wittich A., Fleckenstein M., et al., for the FAM Study Group. Progression of geographic atrophy and impact of fundus autofluorescence patterns in age-related macular degeneration. Am J Ophthalmol 143 (2007) 463-472
133. Sarks J.P., Sarks S.H., and Killingsworth M.C. Morphology of early choroidal neovascularisation in age-related macular degeneration: correlation with activity. Eye 11 (1997) 515-522
134. Gass J.D. Choroidal neovascular membranes-their visualization and treatment. Trans Am Acad Ophthalmol Otolaryngol 77 (1973) OP310-OP320
135. Grossniklaus H.E., and Green W.R. Choroidal neovascularization. Am J Ophthalmol 137 (2004) 496-503
136. Kim S.Y., Sadda S., Pearlman J., et al. Morphometric analysis of the macula in eyes with disciform age-related macular degeneration. Retina 22 (2002) 471-477
137. Green W.R., and Key III S.N. Senile macular degeneration: a histopathologic study. Trans Am Ophthalmol Soc 75 (1977) 180-254
138. Penfold P.L., Provis J.M., and Billson F.A. Age-related macular degeneration: ultrastructural studies of the relationship of leucocytes to angiogenesis. Graefes Arch Clin Exp Ophthalmol 225 (1987) 70-76
139. Dastgheib K., and Green W.R. Granulomatous reaction to Bruch's membrane in age-related macular degeneration. Arch Ophthalmol 112 (1994) 813-818
140. Hageman G.S., Luthert P.J., Victor Chong N.H., Johnson L.V., Anderson D.H., and Mullins R.F. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch's membrane interface in aging and age-related macular degeneration. Prog Retin Eye Res 20 (2001) 705-732
141. Penfold P.L., Madigan M.C., Gillies M.C., and Provis J.M. Immunological and aetiological aspects of macular degeneration. Prog Retin Eye Res 20 (2001) 385-414
142. Anderson D.H., Mullins R.F., Hageman G.S., and Johnson L.V. A role for local inflammation in the formation of drusen in the aging eye. Am J Ophthalmol 134 (2002) 411-431
143. Chen J., Connor K.M., and Smith L.E. Overstaying their welcome: defective CX3CR1 microglia eyed in macular degeneration. J Clin Invest 117 (2007) 2758-2762
144. Oka C., Tsujimoto R., Kajikawa M., et al. HtrA1 serine protease inhibits signaling mediated by Tgfbeta family proteins. Development 131 (2004) 1041-1053
145. Chan C.C., Shen D.F., Zhou M., et al. Human HtrA1 in the eyes with age-related macular degeneration. Trans Am Ophthalmol Soc 105 (2007) 92-98
146. Allikmets R., and Dean D. Bringing age-related macular degeneration into focus. Nat Genet 40 (2008) 820-821
147. Tomany S., Wang J., van Leeuwen R., et al. Risk factors for incident age-related macular degeneration. Pooled findings from 3 continents. Ophthalmology 111 (2004) 1280-1287
148. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene and the incidence of lung cancer and other cancers in male smokers. N Engl J Med 330 (1994) 1029-1035
149. Omenn G.S., Goodman G.E., Thornquist M.D., et al. Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 334 (1996) 1150-1155
150. Bjelakovic G., Nikolova D., Gluud L.L., Simonetti R.G., and Gluud C. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297 (2007) 842-857
151. Albanes D. Letter to the editor. JAMA 298 (2007) 400
152. Gluud L.L., Bjelakovic G., Niklova D., Simonetti R.G., and Gluud C. Response from authors. JAMA 298 (2007) 402-403
153. Huang H.Y., Teutsch S., and Bass E. Letter to the editor. JAMA 298 (2007) 400-401
154. Miller III E.R., Pastor-Barriuso R., Dalal D., Riemersma R.A., Appel L.J., and Guallar E. Meta-analysis: high dosage vitamin E supplementation may increase all-cause mortality. Ann Intern Med 142 (2005) 37-46
155. Chew E.Y., and Clemons T. Vitamin E and the Age-Related Eye Disease Study supplementation for age-related macular degeneration. Arch Ophthalmol 123 (2005) 395-396
156. Complications of Age-Related Macular Degeneration Prevention Trail Research Group. Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. Ophthalmology 113 (2006) 1974-1986
157. Owen S.L., Bunce C., Brannon A.J., et al. Prophylactic laser treatment hastens choroidal neovascularization in unilateral age-related maculopathy: final results of the drusen laser study. Am J Ophthalmol 141 (2006) 276-281
158. Friberg T.R., Musch D.C., Lim J.I., et al. Prophylactic treatment of age-related macular degeneration report number 1: 810-nanometer laser to eyes with drusen. Unilaterally eligible patients. Ophthalmology 113 (2006) 612-622
159. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch Ophthalmol 104 (1986) 694-701
160. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration: results of a randomized clinical trial. Arch Ophthalmol 100 (1982) 912-918
161. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol 119 (2001) 198-207
162. Verteporfin Roundtable 2000 and 2001 Participants, TAP study group principal investigators; VIP study group principal investigators. Guidelines for using verteporfin (visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 22 (2002) 6-18
163. Gragoudas E.S., Adamis A.P., Cunningham E.T., et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 351 (2004) 2805-2816
164. Rosenfeld P.J., Brown D.M., Heier J.S., et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1419-1431
165. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355 (2006) 1432-1444
166. Steinbrook R. The price of sight-ranibizumab, bevacizumab, and the treatment of macular degeneration. N Engl J Med 335 (2006) 1409-1412